348P - The prognostic role of gender and MGMT methylation status in glioblastoma patients: the female power

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Biomarkers
Central Nervous System Malignancies
Presenter Alicia Tosoni
Citation Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366
Authors A. Tosoni1, E. Franceschi1, R. Depenni2, B. Urbini3, M. Faedi4, M. Michiara5, C. Biasini6, E. Giombelli7, G. Pavesi8, F. Zanelli9, M.A. Cavallo10, L. Tosatto11, A. Fioravanti12, E. Zunarelli13, G. Lanza14, D. Bartolini15, E.M. Silini16, A.A. Brandes1
  • 1Medical Oncology, Ausl / Irccs Institute Of Neurological Sciences, Bellaria Hospital, 40139 - Bologna/IT
  • 2Department Of Oncology, Modena University Hospital, 41124 - Modena/IT
  • 3Clinical Oncology Unit, St Anna University Hospital, Ferrara/IT
  • 4Department Of Oncology And Hematology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - IRCCS, Cesena/IT
  • 5Department Of Medical Oncology, University Hospital of Parma, Parma/IT
  • 6Department Of Oncology And Hematology, Oncology Unit, Azienda Ospedaliera Guglielmo da Saliceto, Piacenza/IT
  • 7Neurosurgery, Hospital and University of Parma, Parma/IT
  • 8Department Of Neurosurgery, Ospedale S. Agostino-Estense, Modena/IT
  • 9Department Of Medical Oncology, Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, 42100 - Reggio Emilia/IT
  • 10Department Of Neurosurgery, St Anna University Hospital, Ferrara/IT
  • 11Neurosurgery, Bufalini Hospital, Cesena/IT
  • 12Neurosurgery, Ausl / Irccs Institute Of Neurological Sciences, Bellaria Hospital, 40139 - Bologna/IT
  • 13Department Of Pathology, University Hospital, Modena, Modena/IT
  • 14Department Of Pathology, S. Anna University Hospital and University of Ferrara, Ferrara/IT
  • 15Department Of Pathology, Bufalini Hospital, Cesena/IT
  • 16Departments Of Pathology, University Hospital, Parma, Parma/IT

Abstract

Background

Glioblastoma (GBM) remains an incurable disease. Radiotherapy and temozolomide are the backbone of the treatment. Clinical and molecular factors are essential to define prognosis.

Methods

Data on all new cases of primary brain tumors observed from January 1, 2009, to December 31, 2010, in adults residing within the Emilia-Romagna region were recorded in a prospective registry in the Project of Emilia Romagna on Neuro-Oncology (PERNO). We perform a prospective evaluation about prognostic factors in GBM patients treated with temozolomide concurrent with and adjuvant to radiotherapy.

Results

One hundred sixty-nine GBM patients (median age, 60 years; range 29 – 82) were prospectively evaluated. MGMT methylation status was available in 140 patients. Combining gender and MGMT methylation status we obtained four groups of patients: 36 male pts with methylated MGMT (25.7%), 47 male pts with unmethylated MGMT (33.6%), 32 female pts with methylated MGMT (22.9%), 25 female pts with unmethylated MGMT (17.9%). Results of univariate analysis are summarized in the Table. Overall survival (OS) was significantly different between methylated male and methylated female (p = 0.028), methylated male and unmethylated female (p = 0.031), unmethylated male and methylated female (p = 0.002), methylated female and unmethylated female (p 

Conclusions

The median overall survival is consistently higher for female pts with methylated MGMT, treated with temozolomide concurrent with and adjuvant to radiotherapy. When considered simultaneously with MGMT methylation status, gender might impact on clinical outcome and should be considered as a prognostic factor.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.